{
  "citations" : [],
  "guideline" : {
    "objCls" : "Guideline Annotation",
    "id" : "PA166105003",
    "name" : "Annotation of CPIC Guideline for allopurinol and HLA-B",
    "alternateDrugAvailable" : true,
    "cancerGenome" : false,
    "crossReferences" : [
      {
        "id" : 1447983440,
        "name" : "CPIC® Guideline for Allopurinol and HLA-B – CPIC",
        "resource" : "URL",
        "resourceId" : "https://cpicpgx.org/guidelines/guideline-for-allopurinol-and-hla-b/",
        "_url" : "https://cpicpgx.org/guidelines/guideline-for-allopurinol-and-hla-b/",
        "version" : 1
      }
    ],
    "descriptiveVideoId" : "8LF_sTtUCXY",
    "dosingInformation" : false,
    "hasTestingInfo" : false,
    "history" : [
      {
        "id" : 1183699762,
        "date" : "2012-10-17T00:00:00-07:00",
        "type" : "Create",
        "version" : 0
      },
      {
        "id" : 1444841843,
        "date" : "2015-06-11T15:10:54.200-07:00",
        "description" : "Published update",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1444841850,
        "date" : "2015-06-12T08:50:16.155-07:00",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1450042999,
        "date" : "2018-11-19T14:34:36.346-08:00",
        "description" : "Updated link to new guideline video",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1451461980,
        "date" : "2021-06-16T18:47:56.594-07:00",
        "description" : "Added text from guideline regarding pediatrics",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1452137480,
        "date" : "2023-06-22T18:27:07.674-07:00",
        "description" : "Added supplemental file links",
        "type" : "Update",
        "version" : 0
      }
    ],
    "literature" : [
      {"id":15090607,"title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update.","_sameAs":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4675696","crossReferences":[{"id":1449286509,"resource":"PubMed Central","resourceId":"PMC4675696","_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4675696"},{"id":1449286508,"resource":"PubMed","resourceId":"26094938","_url":"https://www.ncbi.nlm.nih.gov/pubmed/26094938"},{"id":1449286510,"resource":"DOI","resourceId":"10.1002/cpt.161","_url":"http://dx.doi.org/10.1002%2Fcpt.161"}],"objCls":"Literature","pubDate":"2016-01-01T00:00:00-08:00","terms":[{"id":1454108620,"resource":"ClinPGx Tags","term":"CPIC","termId":"pgkbTags:1454108620"},{"id":1451577480,"resource":"PGx Paper Types","term":"Implementation","termId":"pgxPaperTypes:1451577480"}],"type":"Literature"},
      {"id":15033427,"title":"Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing.","_sameAs":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3564416","crossReferences":[{"id":1449274192,"resource":"PubMed Central","resourceId":"PMC3564416","_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3564416"},{"id":1449274191,"resource":"PubMed","resourceId":"23232549","_url":"https://www.ncbi.nlm.nih.gov/pubmed/23232549"},{"id":1449274193,"resource":"DOI","resourceId":"10.1038/clpt.2012.209","_url":"http://dx.doi.org/10.1038%2Fclpt.2012.209"}],"objCls":"Literature","pubDate":"2013-02-01T00:00:00-08:00","terms":[{"id":1454108620,"resource":"ClinPGx Tags","term":"CPIC","termId":"pgkbTags:1454108620"},{"id":1451577480,"resource":"PGx Paper Types","term":"Implementation","termId":"pgxPaperTypes:1451577480"}],"type":"Literature"}
    ],
    "otherPrescribingGuidance" : false,
    "pediatric" : true,
    "recommendation" : true,
    "relatedAlleles" : [
      {
        "objCls" : "Haplotype",
        "id" : "PA165987831",
        "symbol" : "HLA-B*58:01",
        "name" : "*58:01",
        "version" : 4
      }
    ],
    "relatedChemicals" : [
      {
        "objCls" : "Chemical",
        "id" : "PA448320",
        "name" : "allopurinol",
        "version" : 11
      }
    ],
    "relatedGenes" : [
      {
        "objCls" : "Gene",
        "id" : "PA35056",
        "symbol" : "HLA-B",
        "name" : "major histocompatibility complex, class I, B",
        "version" : 40
      }
    ],
    "source" : "CPIC",
    "summaryMarkdown" : {
      "id" : 1447981950,
      "html" : "<p>Allopurinol is contraindicated in individuals with the HLA-B*58:01 variant allele (&quot;HLA-B*58:01-positive&quot;) due to significantly increased risk of allopurinol-induced SCAR.</p>\n",
      "version" : 0
    },
    "terms" : [],
    "textMarkdown" : {
      "id" : 1451433640,
      "html" : "<p>This annotation is based on the <a rel=\"noopener noreferrer\" href=\"https://cpicpgx.org/guidelines/guideline-for-allopurinol-and-hla-b/\" target=\"_blank\">CPIC&reg; guideline for allopurinol and HLA-B</a>.</p>\n<h3 id=\"january-2016-update\">January 2016 Update</h3>\n<p><em>Accepted article preview online June 2015</em></p>\n<p>The 2015 update of CPIC guidelines regarding allopurinol has been published in <em>Clinical Pharmacology and Therapeutics</em>.  Recent literature was reviewed and there is <strong>no new evidence that would change the original guidelines. Therefore, the dosing recommendations in the original publication remain clinically current</strong>.</p>\n<ul>\n<li>Excerpt from guideline update:\n<ul>\n<li>&quot;Although none of the evidence linking HLA-B*58:01 to allopurinol hypersensitivity was conducted in children, there is no reason to suspect that children positive for HLA-B*58:01 would be at less risk of allopurinol hypersensitivity reactions than adults positive for HLA-B*58:01.&quot;</li>\n</ul>\n</li>\n<li>Download and read:\n<ul>\n<li><a rel=\"noopener noreferrer\" href=\"https://files.cpicpgx.org/data/guideline/publication/allopurinol/2015/26094938.pdf\" target=\"_blank\">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Human Leukocyte Antigen-B (HLA-B) Genotype and Allopurinol Dosing: 2015 update </a></li>\n<li><a rel=\"noopener noreferrer\" href=\"https://files.cpicpgx.org/data/guideline/publication/allopurinol/2015/26094938-supplement.pdf\" target=\"_blank\">2015 supplement</a>.</li>\n<li><a href=\"/page/hlabRefMaterials\">HLA Gene-Specific Information Tables</a></li>\n<li><a rel=\"noopener noreferrer\" href=\"https://files.cpicpgx.org/data/report/current/drug_resource/allopurinol-Drug_Resource_Mappings.xlsx\" target=\"_blank\">Allopurinol Drug Resource Mappings</a></li>\n<li><a rel=\"noopener noreferrer\" href=\"https://files.cpicpgx.org/data/report/current/test_alert/allopurinol_Pre_and_Post_Test_Alerts.xlsx\" target=\"_blank\">Allopurinol  Pre and Post Tests Alerts</a></li>\n<li><a rel=\"noopener noreferrer\" href=\"https://files.cpicpgx.org/images/flow_chart/Allopurinol_CDS_Flow_Chart.jpg\" target=\"_blank\">Allopurinol  Clinical Decision Support Flow Chart</a></li>\n</ul>\n</li>\n</ul>\n<h3 id=\"february-2013\">February 2013</h3>\n<p><em>Advanced online publication December 2012</em></p>\n<ul>\n<li>Guidelines regarding the use of pharmacogenomic tests in dosing for allopurinol have been published in Clinical Pharmacology and Therapeutics by the <a rel=\"noopener noreferrer\" href=\"https://cpicpgx.org\" target=\"_blank\">Clinical Pharmacogenetics Implementation Consortium (CPIC)</a>.</li>\n<li>These guidelines are applicable to:\n<ul>\n<li>adults</li>\n</ul>\n</li>\n<li>Excerpt from the 2013 allopurinol dosing guidelines:\n<ul>\n<li>&quot;Allopurinol is the most commonly used drug for the treatment of hyperuricemia and gout; however, allopurinol is also one of the most common causes of severe cutaneous adverse reactions (SCAR), which includes drug hypersensitivity syndrome, Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). A variant allele of the human leukocyte antigen-B, HLA-B*5801, associates strongly with allopurinol-induced SCAR. We have summarized evidence from the published literatures and develop peer-reviewed guidelines for allopurinol use based on HLA-B genotype.&quot;</li>\n</ul>\n</li>\n<li>Download and read:\n<ul>\n<li><a rel=\"noopener noreferrer\" href=\"https://files.cpicpgx.org/data/guideline/publication/allopurinol/2013/23232549.pdf\" target=\"_blank\">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Human Leukocyte Antigen-B Genotype and Allopurinol Dosing </a></li>\n<li><a rel=\"noopener noreferrer\" href=\"https://files.cpicpgx.org/data/guideline/publication/allopurinol/2013/23232549-supplement.pdf\" target=\"_blank\">2013 supplement</a>.</li>\n</ul>\n</li>\n</ul>\n<h3 id=\"table-1-recommended-dosing-of-allopurinol-based-on-hla-b-genotype\">Table 1: Recommended dosing of allopurinol based on <em>HLA-B</em> genotype</h3>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Likely Phenotype</th>\n<th>Genotypes</th>\n<th>Examples of diplotypes</th>\n<th>Implications for phenotypic measures</th>\n<th>Recommendations for allopurinol therapy</th>\n<th>Classification of recommendation for allopurinol therapy</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>Low or reduced risk of allopurinol SCAR</td>\n<td>Absence of <em>*58:01</em> alleles (reported as &quot;negative&quot; on a genotyping test)</td>\n<td>*X/*X <sup>a</sup></td>\n<td>Low or reduced risk of allopurinol SCAR</td>\n<td>Use allopurinol per standard dosing guidelines</td>\n<td>Strong</td>\n</tr>\n<tr>\n<td>Significantly increased risk of allopurinol SCAR</td>\n<td>Presence of at least one <em>*58:01</em> allele (reported as &quot;positive&quot; on a genotyping test)</td>\n<td><em>*58:01</em>/*X <sup>a</sup> <em>*58:01/*58:01</em></td>\n<td>Significantly increased risk of allopurinol SCAR</td>\n<td>Allopurinol is contraindicated</td>\n<td>Strong</td>\n</tr>\n</tbody>\n</table>\n<p><em>Adapted from Table 2 of the 2013 Guideline Manuscript</em></p>\n<p><sup>a</sup> *X = any <em>HLA-B</em> genotype other than <em>*58:01</em>.</p>\n<p><em>HLA-B</em> = human leukocyte antigen B</p>\n",
      "version" : 3
    },
    "version" : 44
  }
}